Cargando…

Left atrial diameter and atrial fibrillation, but not elevated NT-proBNP, predict the development of pulmonary hypertension in patients with HFpEF

BACKGROUND: The determinants of pulmonary hypertension (PH) due to heart failure with preserved ejection fraction (HFpEF) have been poorly investigated in patients with cardiovascular diseases (CVD). METHODS: From July 1 2017 to March 31 2019, a total of 149 consecutive HFpEF patients hospitalized w...

Descripción completa

Detalles Bibliográficos
Autores principales:	LIU, Yi-Xian, LI, Hui, XIA, Yi-Yuan, XIA, Chun-Lei, QU, Xin-Liang, CHU, Peng, ZHOU, Wen-Yin, ZHU, Lin-Lin, LI, Li, CHEN, Shao-Liang, ZHANG, Jun-Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Science Press 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416065/ https://www.ncbi.nlm.nih.gov/pubmed/32863822 http://dx.doi.org/10.11909/j.issn.1671-5411.2020.07.002

Ejemplares similares

The Relationship between Angiotensin–Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure
por: Zhang, Xiaoliang, et al.
Publicado: (2022)

Aldosterone Antagonism in Atrial Fibrillation: Implications for AF‐Predominant HFpEF
por: Ho, Jennifer E.
Publicado: (2020)

The “Obesity Paradox” in Patients With HFpEF With or Without Comorbid Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2022)

Joint Associations of Obesity and NT‐proBNP With the Incidence of Atrial Fibrillation in the ARIC Study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2019)

Case of Ischemic Hepatitis in the Setting of HFpEF Exacerbated by Persistent Atrial Fibrillation
por: McClairen, Christian, et al.
Publicado: (2022)

Prognostic Impact of Echocardiographic Congestion Grade in HFpEF With and Without Atrial Fibrillation
por: Abe, Haruhiko, et al.
Publicado: (2022)

Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide
por: Amin, Ahmad Shoaib, et al.
Publicado: (2015)

Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
por: Staszewsky, Lidia, et al.
Publicado: (2021)

NT‐proBNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure
por: Whitman, Isaac R., et al.
Publicado: (2019)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation
por: Yang, Yanhua, et al.
Publicado: (2020)

HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction
por: Bosanac, Jure, et al.
Publicado: (2022)

Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2023)

miR−21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation
por: Sieweke, Jan-Thorben, et al.
Publicado: (2020)

Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
por: Chouairi, Fouad, et al.
Publicado: (2021)

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

NT‐proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials
por: Werhahn, Stefanie M., et al.
Publicado: (2021)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2020)

Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP – A narrative review
por: Kerr, Brian, et al.
Publicado: (2022)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

Epicardial Adipose Tissue and Development of Atrial Fibrillation (AFIB) and Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Zain, Sarmad, et al.
Publicado: (2023)

Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation
por: Matusik, Paweł T., et al.
Publicado: (2019)

Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Prognostic value of perioperative NT-proBNP after corrective surgery for pediatric congenital heart defects
por: Lin, Fangqin, et al.
Publicado: (2019)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay
por: Lau, Chin-Shern, et al.
Publicado: (2022)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

The relationship between NT-proBNP and Depression in Patients with Heart Failure
por: Gao, Ying–Hui, et al.
Publicado: (2017)

The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)

Atrial fibrillation screening to prevent stroke in patients with high NT-proBNP - a post-hoc analysis of the randomized LOOP study
por: Diederichsen, S Z, et al.
Publicado: (2023)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n5gtrgi0jj289ra312hcci36g9